Press Releases

September 9, 2021

Summary Toggle Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation
August 31, 2021

Summary Toggle Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation
August 5, 2021

Summary Toggle Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
August 4, 2021

Summary Toggle Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case
July 29, 2021

Summary Toggle Endo Presents New Investigational Collagenase Clostridium Histolyticum Data at the American Podiatric Medical Association Annual Scientific Meeting
July 22, 2021

Summary Toggle Endo Announces Agreement in Principle to Settle Tennessee State Court Case
July 15, 2021

Summary Toggle Endo Comments on Tennessee Appeals Court Orders
June 24, 2021

Summary Toggle Endo to Announce Second Quarter 2021 Financial Results
June 24, 2021

Summary Toggle Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021
June 11, 2021

Summary Toggle Tennessee Court Of Appeals Issues Orders Regarding State Court Default Judgment Against Endo
June 9, 2021

Summary Toggle Paladin Labs Inc. Announces Approval of Wakix® (pitolisant) in Canada
May 12, 2021

Summary Toggle Endo to Participate at 2021 RBC Capital Markets Global Healthcare Virtual Conference
May 6, 2021

Summary Toggle Endo Reports First-Quarter 2021 Financial Results And Updates 2021 Financial Guidance
April 29, 2021

Summary Toggle Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at The Aesthetic Meeting 2021
April 27, 2021

Summary Toggle Endo Implements Board Succession Plan
April 13, 2021

Summary Toggle Endo to Announce First Quarter 2021 Financial Results
April 13, 2021

Summary Toggle Endo Announces Publication of Phase 3 Qwo® (collagenase clostridium histolyticum-aaes) Data in Peer-Reviewed Dermatologic Surgery
April 12, 2021

Summary Toggle ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada
April 7, 2021

Summary Toggle Endo Comments on Entry of Default Liability Judgment in Tennessee State Court Case
March 11, 2021

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
March 11, 2021

Summary Toggle Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
March 4, 2021

Summary Toggle Endo International plc Commences Refinancing of its Existing Term Loan
February 25, 2021

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
February 17, 2021

Summary Toggle Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference
February 17, 2021

Summary Toggle Endo Appoints Jennifer M. Chao to Board of Directors
January 26, 2021

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results
January 5, 2021

Summary Toggle Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada
January 5, 2021

Summary Toggle Endo Aesthetics Launches "Really Cellulite" Campaign
January 4, 2021

Summary Toggle Endo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States
December 18, 2020

Summary Toggle Endo to Participate at J.P. Morgan 39th Annual Healthcare Conference
December 2, 2020

Summary Toggle Endo Completes Acquisition of BioSpecifics
November 18, 2020

Summary Toggle Endo to Participate In Upcoming Investor Conferences
November 18, 2020

Summary Toggle Endo Announces Expiration Of Hart-Scott-Rodino Waiting Period For BioSpecifics Tender Offer
November 5, 2020

Summary Toggle Endo Reports Third-Quarter 2020 Financial Results And Raises Full Year 2020 Financial Guidance
November 5, 2020

Summary Toggle Endo Announces Strategic Actions to Further Position the Company for Long-Term Success
November 2, 2020

Summary Toggle Endo International plc Commences Tender Offer for All Outstanding Shares of BioSpecifics Technologies Corp.
October 22, 2020

Summary Toggle Envarsus® PA Once-daily Immunosuppressive Therapy for Kidney and Liver Transplant Patients is Now Reimbursed in Ontario, Quebec, Manitoba and Saskatchewan
October 19, 2020

Summary Toggle Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™
October 9, 2020

Summary Toggle Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery's Annual Meeting (ASDS)
October 7, 2020

Summary Toggle Endo to Announce Third Quarter 2020 Financial Results
October 6, 2020

Summary Toggle Endo Releases First Environmental, Social and Governance Report
October 1, 2020

Summary Toggle Endo Begins Shipment of Generic Kuvan® Tablets and Powder for Oral Solution (sapropterin dihydrochloride)
September 25, 2020

Summary Toggle Endo Announces Fill-Finish Manufacturing and Services Agreement for Novavax COVID-19 Vaccine Candidate
September 24, 2020

Summary Toggle Endo to Present Qwo™ (collagenase clostridium histolyticum-aaes) Data at Vegas Cosmetic Surgery & Aesthetic Dermatology (VCS)
September 8, 2020

Summary Toggle Endo to Participate at Citi 15th Annual BioPharma Virtual Conference
August 21, 2020

Summary Toggle Endo International plc Announces The Expiration And Final Tender Results Of Its Previously Announced Tender Offer
August 17, 2020

Summary Toggle Endo International plc Commences Tender Offer For Any And All Of Its Outstanding 5.75% Senior Notes Due 2022
August 5, 2020

Summary Toggle Endo Reports Second-Quarter 2020 Financial Results
July 30, 2020

Summary Toggle Endo Announces Second Quarter 2020 Earnings Call Time Change
July 29, 2020

Summary Toggle Endo Appoints M. Christine Smith, Ph.D. to Board of Directors
July 6, 2020

Summary Toggle U.S. FDA Approves Qwo™ (collagenase clostridium histolyticum-aaes), the First Injectable Treatment for Cellulite
June 17, 2020

Summary Toggle New Harris Poll Survey Shows 60% of Women Surveyed Feel It's Their Fault They Have Cellulite
June 16, 2020

Summary Toggle Endo to Announce Second-Quarter 2020 Financial Results
June 15, 2020

Summary Toggle Endo International plc Announces Final Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
May 29, 2020

Summary Toggle Endo International plc Announces Early Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations
May 14, 2020

Summary Toggle Endo to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference
May 14, 2020

Summary Toggle Endo International plc Announces Proposed Exchange Offers And Consent Solicitations
May 7, 2020

Summary Toggle Endo Reports First-Quarter 2020 Financial Results and Provides Update Relating to COVID-19 Pandemic
April 16, 2020

Summary Toggle Endo to Announce First Quarter 2020 Financial Results
February 26, 2020

Summary Toggle Endo Reports Fourth-Quarter And Full-Year 2019 Financial Results
February 19, 2020

Summary Toggle Endo Appoints Mark G. Barberio to Board of Directors
February 19, 2020

Summary Toggle Endo Names Blaise Coleman President and Chief Executive Officer
January 27, 2020

Summary Toggle Endo Begins Shipment of Authorized Generic Version of Carafate® (sucralfate) Oral Suspension in the United States
January 24, 2020

Summary Toggle Endo to Announce Fourth-Quarter and Full-Year 2019 Financial Results
January 10, 2020

Summary Toggle Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million
December 17, 2019

Summary Toggle Endo to Participate at J.P. Morgan Healthcare Conference
December 10, 2019

Summary Toggle Endo Launches Generic Version of Afinitor® (everolimus) Tablets in the United States
November 22, 2019

Summary Toggle Endo to Participate at Bank of America Merrill Lynch Leveraged Finance Conference
November 19, 2019

Summary Toggle Endo Announces FDA's Acceptance of Original Biologics License Application (BLA) for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
November 4, 2019

Summary Toggle Endo Implements CEO Succession Plan
November 4, 2019

Summary Toggle Endo Reports Third-Quarter 2019 Financial Results
October 28, 2019

Summary Toggle Endo Aesthetics Launches New Campaign Elevating Artistry Through Scientific Innovation
October 25, 2019

Summary Toggle Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 Fall Meeting of the Sexual Medicine Society of North America (SMSNA)
October 24, 2019

Summary Toggle Endo Presents Data on the Use of a Standing MRI for the Evaluation of Cellulite at the American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 2, 2019

Summary Toggle Endo to Announce Third-Quarter 2019 Financial Results
September 30, 2019

Summary Toggle Endo Announces Successful Culmination of Litigation Regarding FDA Compounding Policy
September 6, 2019

Summary Toggle Endo Announces Submission of Biologics License Application to FDA for Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
September 5, 2019

Summary Toggle Endo Announces Execution of Final Settlement Agreement and Release Resolving "Track 1" Opioid Cases
September 5, 2019

Summary Toggle Endo to Present New XIAFLEX® (collagenase clostridium histolyticum) Data at the 2019 American Society for Surgery of the Hand's (ASSH) Annual Meeting
September 4, 2019

Summary Toggle Endo Announces Approval of First Generic Orfadin® in U.S.
September 3, 2019

Summary Toggle Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States
August 22, 2019

Summary Toggle Football Legend John Elway Reveals He has Dupuytren's Contracture and Wants Others to Get the "Facts on Hand"
August 20, 2019

Summary Toggle Endo Announces Settlement in Principle to Resolve "Track 1" Opioid Cases
August 5, 2019

Summary Toggle Endo Reports Second-Quarter 2019 Financial Results
August 2, 2019

Summary Toggle Endo Applauds U.S. District Court Decision that Vasopressin Cannot be Used for Compounding by Outsourcing Facilities
August 1, 2019

Summary Toggle Endo Appoints Domenico Ciarico as Executive Vice President and Chief Commercial Officer, Sterile and Generics
July 31, 2019

Summary Toggle Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
July 11, 2019

Summary Toggle Endo to Announce Second-Quarter 2019 Financial Results
June 6, 2019

Summary Toggle Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month
May 17, 2019

Summary Toggle Phase 3 Data of Collagenase Clostridium Histolyticum for the Investigational Treatment of Cellulite to Be Presented at The Aesthetic Meeting 2019
May 15, 2019

Summary Toggle Endo to Participate at RBC Healthcare Conference
May 9, 2019

Summary Toggle Endo Reports First-Quarter 2019 Financial Results
May 1, 2019

Summary Toggle Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
April 10, 2019

Summary Toggle Endo to Announce First-Quarter 2019 Financial Results
April 5, 2019

Summary Toggle Endo Begins Shipment of Authorized Generic Version of PROVENTIL® (albuterol sulfate) HFA Inhalation Aerosol in the United States
March 27, 2019

Summary Toggle Endo International plc Announces Early Tender Results of its Previously Announced Cash Tender Offers and Consent Solicitations for up to $1.5 billion Aggregate Purchase Price of its Outstanding Senior Notes
March 19, 2019

Summary Toggle Endo Announces Publication Of Collagenase Clostridium Histolyticum (CCH) Phase 2 Data In Dermatologic Surgery
March 14, 2019

Summary Toggle Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
March 14, 2019

Summary Toggle Endo International plc Announces an Upsizing of its Cash Tender Offers and Consent Solicitations
March 14, 2019

Summary Toggle Endo International plc Announces Debt Refinancing Transactions, Including Cash Tender Offers and Consent Solicitations for up to $1.0 billion Aggregate Purchase Price of its Outstanding Senior Notes